Biomarkers as new tools to improve the diagnosis and treatment of PTSD (CROSBI ID 50465)
Prilog u knjizi | izvorni znanstveni rad
Podaci o odgovornosti
Pivac, Nela ; Nedić, Gordana ; Kozarić-Kovačić, Dragica ; Nikolac, Matea ; Grubišić-Ilić, Mirjana ; Mustapić, Maja ; Jendričko, Tihana ; Rakoš, Iva ; Muck-Šeler, Dorotea
engleski
Biomarkers as new tools to improve the diagnosis and treatment of PTSD
PTSD is a serious and debilitating psychiatric disorder that can develop in individuals who were exposed to one or more intense traumatic event(s). Since not all people exposed to traumatic experience develop PTSD, it is assumed that different neurobiological, genetic and environmental risk factors are involved in the vulnerability and/or resilience to PTSD. PTSD biomarkers, defined as characteristics that objectively measure and evaluate normal biological processes, pathogenic processes, or pharmacologic responses to a therapeutic intervention, might improve the diagnosis and treatment of PTSD. Determined biomarkers were peripheral biochemical markers such as platelet serotonin (5-HT) concentration, platelet monoamine oxidase type B (MAO-B) activity, plasma dopamine-beta-hydroxylase (DBH) activity, and genetic markers /MAO-B intron 13, -1021C/T DBH, catechol-o-methyltransferase (COMT) val158/108met, brain-derived neurotrophic factor (BDNF) val66met, 102T/C serotonin receptor type 2A gene (5HT2A) polymorphism and serotonin transporter (5HTT) gene-linked polymorphic region (5HTTLPR)/. Study participants were Croatian male war veterans with or without current and chronic combat-related PTSD, recruited from the Referral Centre for the Stress-related Disorders of the University Hospital Dubrava, Zagreb. Only plasma DBH activity, but not other markers, differed significantly between war veterans with or without PTSD. When veterans were subdivided according to the narrow clinical symptoms (such as psychotic features, sleep disturbances, suicidal behavior), platelet 5-HT concentration, platelet MAO-B activity, and val66met BDNF were significantly different among these groups. The results indicate that specific PTSD biomarkers, associated with the narrow clinical features, might be indicators of PTSD traits, state or progression, and might be used to improve the diagnosis and treatment of PTSD.
PTSD, war veterans, biochemical markers, genes, narrow clinical features, polymorphisms, risk factors
ISSN 1874-6276
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
nije evidentirano
Podaci o prilogu
21-74.
objavljeno
Podaci o knjizi
New tools to enhance posttraumatic stress disorder diagnosis and treatment : invisible wounds of war
Wiederhold, Brenda K.
Amsterdam: IOS Press
2013.
978-1-61499-188-5